Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study

OBJECTIVE: Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of various ADAs used as add-on medication to metformin in T2DM patients from a natio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Cheng-Wei, Yu, Chu-Leng, Lin, Jiunn-Cherng, Hsieh, Yu-Cheng, Lin, Che-Chen, Hung, Chen-Ying, Li, Cheng-Hung, Liao, Ying-Chieh, Lo, Chu-Pin, Huang, Jin-Long, Lin, Ching-Heng, Wu, Tsu-Juey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781294/
https://www.ncbi.nlm.nih.gov/pubmed/29368615
http://dx.doi.org/10.1186/s12933-018-0663-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781294/
https://www.ncbi.nlm.nih.gov/pubmed/29368615
http://dx.doi.org/10.1186/s12933-018-0663-6

Ejemplares similares